The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Addiction to Oncogenes--the Achilles Heal of Cancer
Abstract
Mechanisms of Acquired Resistance and Tolerance to EGFR Targeted Therapy in Non-Small Cell Lung Cancer,
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Nowell, P. C. (1976) · Science · doi:10.1126/science.959840 · Cited by 6,471
Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104
Prediction of central nervous system embryonal tumour outcome based on gene expression
Pomeroy, S. L., Tamayo, P., Gaasenbeek, M., Sturla, L. M., Angelo, M., McLaughlin, M. E., Kim, J. Y. H., Goumnerova, L. C., Black, P. M., Lau, C., et al. (2002) · Nature · doi:10.1038/415436a · Cited by 2,371
Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia
Kantarjian, H., Sawyers, C., Hochhaus, A., Guilhot, F., Schiffer, C., Gambacorti-Passerini, C., Niederwieser, D., Resta, D., Capdeville, R., Zoellner, U., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011573 · Cited by 2,019
Vogel, C. L., Cobleigh, M. A., Tripathy, D., Gutheil, J. C., Harris, L. N., Fehrenbacher, L., Slamon, D. J., Murphy, M., Novotny, W. F., Burchmore, M., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.3.719 · Cited by 1,860
Reversible Tumorigenesis by MYC in Hematopoietic Lineages
Felsher, D. W., & Bishop, J. M. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80367-6 · Cited by 881
Essential role for oncogenic Ras in tumour maintenance
Chin, L., Tam, A., Pomerantz, J., Wong, M., Holash, J., Bardeesy, N., Shen, Q., O'Hagan, R., Pantginis, J., Zhou, H., et al. (1999) · Nature · doi:10.1038/22788 · Cited by 875
Sustained Loss of a Neoplastic Phenotype by Brief Inactivation of MYC
Jain, M., Arvanitis, C., Chu, K., Dewey, W., Leonhardt, E., Trinh, M., Sundberg, C. D., Bishop, J. M., & Felsher, D. W. (2002) · Science · doi:10.1126/science.1071489 · Cited by 644
Pelengaris, S., Khan, M., & Evan, G. I. (2002) · Cell · doi:10.1016/s0092-8674(02)00738-9 · Cited by 626
Cited by
Items 101–200 of 201
Oncogene addiction: setting the stage for molecularly targeted cancer therapy
Sharma, S. V., & Settleman, J. (2007) · Genes & Development · doi:10.1101/gad.1609907 · Cited by 441
Pathogenesis of Human B Cell Lymphomas
Shaffer, A. L., Young, R. M., & Staudt, L. M. (2012) · Annual Review of Immunology · doi:10.1146/annurev-immunol-020711-075027 · Cited by 437
Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival
Hamilton, A., Helgason, G. V., Schemionek, M., Zhang, B., Myssina, S., Allan, E. K., Nicolini, F. E., Müller-Tidow, C., Bhatia, R., Brunton, V. G., et al. (2012) · Blood · doi:10.1182/blood-2010-12-326843 · Cited by 435
A SUMOylation-Dependent Transcriptional Subprogram Is Required for Myc-Driven Tumorigenesis
Kessler, J. D., Kahle, K. T., Sun, T., Meerbrey, K. L., Schlabach, M. R., Schmitt, E. M., Skinner, S. O., Xu, Q., Li, M. Z., Hartman, Z. C., et al. (2012) · Science · doi:10.1126/science.1212728 · Cited by 433
The evolving concept of cancer and metastasis stem cells
Baccelli, I., & Trumpp, A. (2012) · Journal of Cell Biology · doi:10.1083/jcb.201202014 · Cited by 412
Cyclin D1 in Breast Cancer Pathogenesis
Arnold, A., & Papanikolaou, A. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.064 · Cited by 411
Bao, Z.-S., Chen, H.-M., Yang, M.-Y., Zhang, C.-B., Yu, K., Ye, W.-L., Hu, B.-Q., Yan, W., Zhang, W., Akers, J., et al. (2014) · Genome Research · doi:10.1101/gr.165126.113 · Cited by 409
Cellular senescence is an important mechanism of tumor regression upon c-Myc inactivation
Wu, C.-H., van Riggelen, J., Yetil, A., Fan, A. C., Bachireddy, P., & Felsher, D. W. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0701953104 · Cited by 403
Zuo, T., Wang, L., Morrison, C., Chang, X., Zhang, H., Li, W., Liu, Y., Wang, Y., Liu, X., Chan, M. W. Y., et al. (2007) · Cell · doi:10.1016/j.cell.2007.04.034 · Cited by 395
Chakravarty, D., Santos, E., Ryder, M., Knauf, J. A., Liao, X.-H., West, B. L., Bollag, G., Kolesnick, R., Thin, T. H., Rosen, N., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci46382 · Cited by 391
New approaches to molecular cancer therapeutics
Collins, I., & Workman, P. (2006) · Nature Chemical Biology · doi:10.1038/nchembio840 · Cited by 391
Degradation of AMPK by a Cancer-Specific Ubiquitin Ligase
Pineda, C. T., Ramanathan, S., Fon Tacer, K., Weon, J. L., Potts, M. B., Ou, Y.-H., White, M. A., & Potts, P. R. (2015) · Cell · doi:10.1016/j.cell.2015.01.034 · Cited by 389
Translational Control in Cancer Etiology
Ruggero, D. (2013) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a012336 · Cited by 367
Non-Oncogene Addiction and the Stress Phenotype of Cancer Cells
Solimini, N. L., Luo, J., & Elledge, S. J. (2007) · Cell · doi:10.1016/j.cell.2007.09.007 · Cited by 365
STAT3 as a central mediator of neoplastic cellular transformation
Frank, D. A. (2007) · Cancer Letters · doi:10.1016/j.canlet.2006.10.017 · Cited by 364
Lineage dependency and lineage-survival oncogenes in human cancer
Garraway, L. A., & Sellers, W. R. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1947 · Cited by 360
McDermott, U., Sharma, S. V., Dowell, L., Greninger, P., Montagut, C., Lamb, J., Archibald, H., Raudales, R., Tam, A., Lee, D., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0707498104 · Cited by 356
Chemogenomics: an emerging strategy for rapid target and drug discovery
Bredel, M., & Jacoby, E. (2004) · Nature Reviews Genetics · doi:10.1038/nrg1317 · Cited by 356
Saal, L. H., Gruvberger-Saal, S. K., Persson, C., Lövgren, K., Jumppanen, M., Staaf, J., Jönsson, G., Pires, M. M., Maurer, M., Holm, K., et al. (2008) · Nature Genetics · doi:10.1038/ng.2007.39 · Cited by 355
Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4
Program, N. C. S., Prickett, T. D., Agrawal, N. S., Wei, X., Yates, K. E., Lin, J. C., Wunderlich, J. R., Cronin, J. C., Cruz, P., Rosenberg, S. A., et al. (2009) · Nature Genetics · doi:10.1038/ng.438 · Cited by 352
Addiction to protein kinase CK2: A common denominator of diverse cancer cells?
Ruzzene, M., & Pinna, L. A. (2010) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2009.07.018 · Cited by 352
Squamous Cell Carcinoma of the Lung: Molecular Subtypes and Therapeutic Opportunities
Perez-Moreno, P., Brambilla, E., Thomas, R., & Soria, J.-C. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2370 · Cited by 348
Ten things you should know about protein kinases: IUPHAR R eview 14
Fabbro, D., Cowan‐Jacob, S. W., & Moebitz, H. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13096 · Cited by 347
Emerging Paradigms in the Development of Resistance to Tyrosine Kinase Inhibitors in Lung Cancer
Gainor, J. F., & Shaw, A. T. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.2029 · Cited by 346
Translating cancer research into targeted therapeutics
de Bono, J. S., & Ashworth, A. (2010) · Nature · doi:10.1038/nature09339 · Cited by 335
The aurora kinases in cell cycle and leukemia
Goldenson, B., & Crispino, J. D. (2015) · Oncogene · doi:10.1038/onc.2014.14 · Cited by 334
Targeting the Eukaryotic Translation Initiation Factor 4E for Cancer Therapy
Graff, J. R., Konicek, B. W., Carter, J. H., & Marcusson, E. G. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5635 · Cited by 332
Fogal, V., Richardson, A. D., Karmali, P. P., Scheffler, I. E., Smith, J. W., & Ruoslahti, E. (2010) · Molecular and Cellular Biology · doi:10.1128/mcb.01101-09 · Cited by 329
Targeting the mTOR signaling network in cancer
Chiang, G. G., & Abraham, R. T. (2007) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2007.08.001 · Cited by 327
A community computational challenge to predict the activity of pairs of compounds
Community, N.-D., Bansal, M., Yang, J., Karan, C., Menden, M. P., Costello, J. C., Tang, H., Xiao, G., Li, Y., Allen, J., et al. (2014) · Nature Biotechnology · doi:10.1038/nbt.3052 · Cited by 321
Synthetic lethality: General principles, utility and detection using genetic screens in human cells
Nijman, S. M. B. (2011) · FEBS Letters · doi:10.1016/j.febslet.2010.11.024 · Cited by 319
Medical therapies for hepatocellular carcinoma: a critical view of the evidence
Villanueva, A., Hernandez-Gea, V., & Llovet, J. M. (2013) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2012.199 · Cited by 314
Visceral obesity, metabolic syndrome, insulin resistance and cancer
Doyle, S. L., Donohoe, C. L., Lysaght, J., & Reynolds, J. V. (2012) · Proceedings of the Nutrition Society · doi:10.1017/s002966511100320x · Cited by 309
The New Era in Cancer Research
Varmus, H. (2006) · Science · doi:10.1126/science.1126758 · Cited by 308
Raha, D., Wilson, T. R., Peng, J., Peterson, D., Yue, P., Evangelista, M., Wilson, C., Merchant, M., & Settleman, J. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3456 · Cited by 307
Dual Targeting of HSC70 and HSP72 Inhibits HSP90 Function and Induces Tumor-Specific Apoptosis
Powers, M. V., Clarke, P. A., & Workman, P. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.08.002 · Cited by 307
Sun, C., Hobor, S., Bertotti, A., Zecchin, D., Huang, S., Galimi, F., Cottino, F., Prahallad, A., Grernrum, W., Tzani, A., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.02.045 · Cited by 304
Factors underlying sensitivity of cancers to small-molecule kinase inhibitors
Jänne, P. A., Gray, N., & Settleman, J. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2871 · Cited by 303
Molecular biology of lung cancer.
Cooper, W. A., Lam, D. C.-L., O'Toole, S. A., & Minna, J. D. (2013) · PubMed · doi:10.3978/j.issn.2072-1439.2013.08.03 · Cited by 303
She, Q.-B., Chandarlapaty, S., Ye, Q., Lobo, J., Haskell, K. M., Leander, K. R., DeFeo-Jones, D., Huber, H. E., & Rosen, N. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003065 · Cited by 301
RetractedAkt–RSK–S6 Kinase Signaling Networks Activated by Oncogenic Receptor Tyrosine Kinases
Moritz, A., Li, Y., Guo, A., Villén, J., Wang, Y., MacNeill, J., Kornhauser, J., Sprott, K., Zhou, J., Possemato, A., et al. (2010) · Science Signaling · doi:10.1126/scisignal.2000998 · Cited by 300
Probing the Probes: Fitness Factors For Small Molecule Tools
Workman, P., & Collins, I. (2010) · Chemistry & Biology · doi:10.1016/j.chembiol.2010.05.013 · Cited by 299
A Translational View of the Molecular Pathogenesis of Lung Cancer
Sato, M., Shames, D. S., Gazdar, A. F., & Minna, J. D. (2007) · Journal of Thoracic Oncology · doi:10.1097/01.jto.0000263718.69320.4c · Cited by 297
Targeting Nuclear Factor-Kappa B to Overcome Resistance to Chemotherapy
Godwin, P., Baird, A. M., Heavey, S., Barr, M. P., O’Byrne, K. J., & Gately, K. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00120 · Cited by 296
The somatic mutation theory of cancer: growing problems with the paradigm?
Soto, A. M., & Sonnenschein, C. (2004) · BioEssays · doi:10.1002/bies.20087 · Cited by 295
Mir, S. E., De Witt Hamer, P. C., Krawczyk, P. M., Balaj, L., Claes, A., Niers, J. M., Van Tilborg, A. A. G., Zwinderman, A. H., Geerts, D., Kaspers, G. J. L., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.08.011 · Cited by 294
Shima, F., Yoshikawa, Y., Ye, M., Araki, M., Matsumoto, S., Liao, J., Hu, L., Sugimoto, T., Ijiri, Y., Takeda, A., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1217730110 · Cited by 293
“Cancer cells carrying the ras oncogene are known to exhibit a phenomenon called oncogene addiction, where their survival becomes dependent on the activated oncogene function (3).”
BackgroundMethodMutations and addiction to EGFR: the Achilles ‘heal’ of lung cancers?
Gazdar, A. F., Shigematsu, H., Herz, J., & Minna, J. D. (2004) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2004.08.008 · Cited by 293
Tyrosine kinase gene rearrangements in epithelial malignancies
Shaw, A. T., Hsu, P. P., Awad, M. M., & Engelman, J. A. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3612 · Cited by 292
Riely, G. J., Kris, M. G., Zhao, B., Akhurst, T., Milton, D. T., Moore, E., Tyson, L., Pao, W., Rizvi, N. A., Schwartz, L. H., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0560 · Cited by 287
Towards personalized treatment for early stage HER2-positive breast cancer
Goutsouliak, K., Veeraraghavan, J., Sethunath, V., De Angelis, C., Osborne, C. K., Rimawi, M. F., & Schiff, R. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0299-9 · Cited by 287
DNA Methylation Screening Identifies Driver Epigenetic Events of Cancer Cell Survival
De Carvalho, D. D., Sharma, S., You, J. S., Su, S.-F., Taberlay, P. C., Kelly, T. K., Yang, X., Liang, G., & Jones, P. A. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.03.045 · Cited by 285
Cancer-specific defects in DNA repair pathways as targets for personalized therapeutic approaches
Dietlein, F., Thelen, L., & Reinhardt, H. C. (2014) · Trends in Genetics · doi:10.1016/j.tig.2014.06.003 · Cited by 280
Greulich, H., Kaplan, B., Mertins, P., Chen, T.-H., Tanaka, K. E., Yun, C.-H., Zhang, X., Lee, S.-H., Cho, J., Ambrogio, L., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1203201109 · Cited by 279
Zuber, J., Rappaport, A. R., Luo, W., Wang, E., Chen, C., Vaseva, A. V., Shi, J., Weissmueller, S., Fellman, C., Taylor, M. J., et al. (2011) · Genes & Development · doi:10.1101/gad.17269211 · Cited by 279
BRAFE600 in benign and malignant human tumours
Michaloglou, C., Vredeveld, L. C. W., Mooi, W. J., & Peeper, D. S. (2008) · Oncogene · doi:10.1038/sj.onc.1210704 · Cited by 275
Kobayashi, S., Ji, H., Yuza, Y., Meyerson, M., Wong, K.-K., Tenen, D. G., & Halmos, B. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1346 · Cited by 272
KRAS G12C NSCLC Models Are Sensitive to Direct Targeting of KRAS in Combination with PI3K Inhibition
Misale, S., Fatherree, J. P., Cortez, E., Li, C., Bilton, S., Timonina, D., Myers, D. T., Lee, D., Gomez-Caraballo, M., Greenberg, M., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0368 · Cited by 259
MicroRNA profile analysis of human prostate cancers
Tong, A. W., Fulgham, P., Jay, C., Chen, P., Khalil, I., Liu, S., Senzer, N., Eklund, A. C., Han, J., & Nemunaitis, J. (2009) · Cancer Gene Therapy · doi:10.1038/cgt.2008.77 · Cited by 271
Renfro, L. A., & Sargent, D. J. (2017) · Annals of Oncology · doi:10.1093/annonc/mdw413 · Cited by 271
Kelloff, G. J., Lippman, S. M., Dannenberg, A. J., Sigman, C. C., Pearce, H. L., Reid, B. J., Szabo, E., Jordan, V. C., Spitz, M. R., Mills, G. B., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1104 · Cited by 270
Zuber, J., McJunkin, K., Fellmann, C., Dow, L. E., Taylor, M. J., Hannon, G. J., & Lowe, S. W. (2011) · Nature Biotechnology · doi:10.1038/nbt.1720 · Cited by 267
Implications of micro-RNA profiling for cancer diagnosis
Cummins, J. M., & Velculescu, V. E. (2006) · Oncogene · doi:10.1038/sj.onc.1209914 · Cited by 266
Pylayeva, Y., Gillen, K. M., Gerald, W., Beggs, H. E., Reichardt, L. F., & Giancotti, F. G. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37160 · Cited by 261
Therapeutic advances of targeting receptor tyrosine kinases in cancer
Tomuleasa, C., Tigu, A.-B., Munteanu, R., Moldovan, C.-S., Kegyes, D., Onaciu, A., Gulei, D., Ghiaur, G., Einsele, H., & Croce, C. M. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01899-w · Cited by 260
Shimamura, T., Lowell, A. M., Engelman, J. A., & Shapiro, G. I. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0933 · Cited by 259
Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death
Chen, R., Keating, M. J., Gandhi, V., & Plunkett, W. (2005) · Blood · doi:10.1182/blood-2005-04-1678 · Cited by 259
The MYC oncogene is a global regulator of the immune response
Casey, S. C., Baylot, V., & Felsher, D. W. (2018) · Blood · doi:10.1182/blood-2017-11-742577 · Cited by 259
MYC Oncogene Contributions to Release of Cell Cycle Brakes
García-Gutiérrez, L., Delgado, M. D., & León, J. (2019) · Genes · doi:10.3390/genes10030244 · Cited by 255
The MET receptor tyrosine kinase in invasion and metastasis
Benvenuti, S., & Comoglio, P. M. (2007) · Journal of Cellular Physiology · doi:10.1002/jcp.21183 · Cited by 253
Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure
Pagliarini, R., Shao, W., & Sellers, W. R. (2015) · EMBO reports · doi:10.15252/embr.201439949 · Cited by 253
Yamaguchi, T., Yanagisawa, K., Sugiyama, R., Hosono, Y., Shimada, Y., Arima, C., Kato, S., Tomida, S., Suzuki, M., Osada, H., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.008 · Cited by 249
The c‐myc Promoter: Still MysterY and Challenge
(2008) · Advances in Cancer Research · doi:10.1016/s0065-230x(07)99004-1 · Cited by 211
An expanded universe of cancer targets
Hahn, W. C., Bader, J. S., Braun, T. P., Califano, A., Clemons, P. A., Druker, B. J., Ewald, A. J., Fu, H., Jagu, S., Kemp, C. J., et al. (2021) · Cell · doi:10.1016/j.cell.2021.02.020 · Cited by 213
Alvarez, M. J., Subramaniam, P. S., Tang, L. H., Grunn, A., Aburi, M., Rieckhof, G., Komissarova, E. V., Hagan, E. A., Bodei, L., Clemons, P. A., et al. (2018) · Nature Genetics · doi:10.1038/s41588-018-0138-4 · Cited by 210
Memarzadeh, S., Xin, L., Mulholland, D. J., Mansukhani, A., Wu, H., Teitell, M. A., & Witte, O. N. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.11.002 · Cited by 201
Altered states: selectively drugging the Hsp90 cancer chaperone
Workman, P. (2004) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2003.12.005 · Cited by 195
Unleashing the power of inhibitors of oncogenic kinases through BH3 mimetics
Cragg, M. S., Harris, C., Strasser, A., & Scott, C. L. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2615 · Cited by 185
KRAS G12C inhibition produces a driver-limited state revealing collateral dependencies
Lou, K., Steri, V., Ge, A. Y., Hwang, Y. C., Yogodzinski, C. H., Shkedi, A. R., Choi, A. L. M., Mitchell, D. C., Swaney, D. L., Hann, B., et al. (2019) · Science Signaling · doi:10.1126/scisignal.aaw9450 · Cited by 175
Fleming, J. B., Shen, G.-L., Holloway, S. E., Davis, M., & Brekken, R. A. (2005) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-04-0206 · Cited by 176
Costa, D. B., Kobayashi, S., Tenen, D. G., & Huberman, M. S. (2007) · Lung Cancer · doi:10.1016/j.lungcan.2007.05.017 · Cited by 160
Molecular mechanisms of resistance in epidermal growth factor receptor-mutant lung adenocarcinomas
Cortot, A. B., & Jänne, P. A. (2014) · European Respiratory Review · doi:10.1183/09059180.00004614 · Cited by 158
Feedback and redundancy in receptor tyrosine kinase signaling: relevance to cancer therapies
Sun, C., & Bernards, R. (2014) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2014.08.010 · Cited by 155
Vertical suppression of the EGFR pathway prevents onset of resistance in colorectal cancers
Misale, S., Bozic, I., Tong, J., Peraza-Penton, A., Lallo, A., Baldi, F., Lin, K. H., Truini, M., Trusolino, L., Bertotti, A., et al. (2015) · Nature Communications · doi:10.1038/ncomms9305 · Cited by 122
TNF-driven adaptive response mediates resistance to EGFR inhibition in lung cancer
Gong, K., Guo, G., Gerber, D. E., Gao, B., Peyton, M., Huang, C., Minna, J. D., Hatanpaa, K. J., Kernstine, K., Cai, L., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci96148 · Cited by 98
Altering chemosensitivity by modulating translation elongation
Robert, F., Carrier, M., Rawe, S., Chen, S., Lowe, S., & Pelletier, J. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005428 · Cited by 90
Green, M. R., Vicente-Dueñas, C., Romero-Camarero, I., Long Liu, C., Dai, B., González-Herrero, I., García-Ramírez, I., Alonso-Escudero, E., Iqbal, J., Chan, W. C., et al. (2014) · Nature Communications · doi:10.1038/ncomms4904 · Cited by 88
Opportunities and challenges in combination gene cancer therapy
Nastiuk, K. L., & Krolewski, J. J. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.12.005 · Cited by 85
“Weinstein IB.”
Backgroundc-MYC—Making Liver Sick: Role of c-MYC in Hepatic Cell Function, Homeostasis and Disease
Zheng, K., Cubero, F., & Nevzorova, Y. (2017) · Genes · doi:10.3390/genes8040123 · Cited by 84
Douglass, E. F., Allaway, R. J., Szalai, B., Wang, W., Tian, T., Fernández-Torras, A., Realubit, R., Karan, C., Zheng, S., Pessia, A., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100492 · Cited by 68
Lelliott, E. J., McArthur, G. A., Oliaro, J., & Sheppard, K. E. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.661737 · Cited by 65
PI3′-Kinase Inhibition Forestalls the Onset of MEK1/2 Inhibitor Resistance in BRAF -Mutated Melanoma
Deuker, M. M., Marsh Durban, V., Phillips, W. A., & McMahon, M. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0856 · Cited by 60
Akgül, S., Patch, A.-M., D’Souza, R. C. J., Mukhopadhyay, P., Nones, K., Kempe, S., Kazakoff, S. H., Jeffree, R. L., Stringer, B. W., Pearson, J. V., et al. (2019) · Cancers · doi:10.3390/cancers11020190 · Cited by 57
Taking advantage of drug resistance, a new approach in the war on cancer
Wang, L., & Bernards, R. (2018) · Frontiers of Medicine · doi:10.1007/s11684-018-0647-7 · Cited by 53
Mundi, P. S., Dela Cruz, F. S., Grunn, A., Diolaiti, D., Mauguen, A., Rainey, A. R., Guillan, K. C., Siddiquee, A., You, D., Realubit, R., et al. (2021) · doi:10.1101/2021.10.03.462951 · Cited by 51
Ligands stimulating antitumour immunity as the next G-quadruplex challenge
Miglietta, G., Marinello, J., Russo, M., & Capranico, G. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01649-y · Cited by 44
“Many efforts have been focused on trying to inhibit single oncogene expression to exploit the tumour addiction phenomena [47] and enhance G4-binder cancer cell killing potency.”
BackgroundJacobi, N., Seeboeck, R., Hofmann, E., Schweiger, H., Smolinska, V., Mohr, T., Boyer, A., Sommergruber, W., Lechner, P., Pichler-Huebschmann, C., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.22475 · Cited by 43
A call to ARMS: targeting the PAX3-FOXO1 gene in alveolar rhabdomyosarcoma
Olanich, M. E., & Barr, F. G. (2013) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2013.772136 · Cited by 39
Targeting fusion protein/corepressor contact restores differentiation response in leukemia cells
Racanicchi, S., Maccherani, C., Liberatore, C., Billi, M., Gelmetti, V., Panigada, M., Rizzo, G., Nervi, C., & Grignani, F. (2005) · The EMBO Journal · doi:10.1038/sj.emboj.7600593 · Cited by 36
Oncogene Overdose: Too Much of a Bad Thing for Oncogene-Addicted Cancer Cells
Amin, A. D., Rajan, S. S., Groysman, M. J., Pongtornpipat, P., & schatz, J. H. (2015) · Biomarkers in Cancer · doi:10.4137/bic.s29326 · Cited by 25
Metadata
- Authors
- Weinstein, I. B.
- Venue
- Science
- Published
- 2002-07-05
- Volume
- 297
- Issue
- 5578
- Pages
- 63-64
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2103894337
- Cited by
- 1,728
- References
- 19
- FWCI
- 33.90
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.